Factors influencing arteriovenous fistula dysfunction in Japanese patients on chronic hemodialysis

International Journal of Artificial Organs

Volumn 22, Issue 1, 1999, Pages 14-17

  Masaki, T ^a   Yorioka, Noriaki ^a   Kyuden, Y ^a   Yamashita, K ^a   Taniguchi, Y ^a   Yamakido, M ^a   Tanaka, J ^a   Harada, S ^b  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b Ichiyou kai Harada Hospital   (Japan)

Author keywords

Angiotensin converting enzyme inhibitors; Fistula dysfunction; Hemodialysis

Indexed keywords

BLOOD PRESSURE; HEMODIALYZERS; REGRESSION ANALYSIS; UREA;

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; ARTERIOVENOUS FISTULAS; BLOOD UREA NITROGENS; COX PROPORTIONAL HAZARD MODEL; DIABETES MELLITUS; FISTULA DYSFUNCTION; HAEMATOCRIT; HAEMODIALYSIS; HEMODIALYSIS PATIENT; STEPWISE REGRESSION ANALYSIS;

DIALYSIS;

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PROTHROMBIN TIME; REGRESSION ANALYSIS; SEX DIFFERENCE; UREA NITROGEN BLOOD LEVEL; VASCULAR ACCESS; VASCULAR SMOOTH MUSCLE;

EID: 0032968436     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889902200104     Document Type: Article

References (17)

1. De Marchi S, Falleti E, Giacomello R et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 1996;7: 1169-77.
2. Goldwasser P, Avram MM, Collier JT, Michel MA, Gusik SA, Mittman N. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 1994; 24: 785-94.
3. Fan P-Y, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3: 1-11.
4. Diskin CJ, Stokes TJ, Jr, Pennell AT. Pharmacologic interventions to prevent hemodialysis vascular access thrombosis. Nephron 1993; 64:1-26.
5. Diskin CJ, Stokes TJ, Thomas SG et al. An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron 1998; 78: 365-8.
6. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE. Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994; 45:177-84.
7. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B 1972; 34: 187-220.
8. Schwab SJ, Raymond JR, Saeed M, Newman GE, Dennis PA, Bollinger RR. Prevention of hemodialysis fistula thrombosis: early detection of venous stenoses. Kidney Int 1989; 36: 707-11
9. Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 1992; 42: 1390-6
10. Windus DW, Jendrisak MD, Delmez JA. Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age. Am J Kidney Dis 1992; 19: 448-52.
11. Zusmann RM. Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int 1984; 25: 969-83.
12. Anderson PW, Zhang XY, Tian J et al. Insulin and angiotensin II are additive in stimulating TGF-ß1 and matrix mRNA in mesangial cells. Kidney Int 1996; 50: 745-53.
13. Anderson PW, Do YS, Hsueh WA. Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993; 21: 29-35.
14. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-ß expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7.
15. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77.
16. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23: 247-54.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 11:1456-62.